Diego Piccioli

Dr. Diego Piccioli

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
Francesca MicoliFrancesca Micoli
Francesca Micoli
RARenzo Alfini
Renzo Alfini
RBRoberta Di Benedetto
Roberta Di Benedetto
FNFrancesca Necchi
Francesca Necchi
FSFabiola Schiavo
Fabiola Schiavo
ASAllan Saul
Allan Saul
Technology platforms are an important strategy to facilitate the design, development and implementation of vaccines to combat high-burden diseases that are still a threat for human populations, especially in low- and middle-income countries, and to address the increasing number and global distribution of pathogens resistant to antimicrobial drugs. Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles derived from engineered Gram-negative bacteria, represent an attractive technology to design affordable vaccines. Here, we show that GMMA, decorated with heterologous polysaccharide or protein antigens, leads to a strong and effective antigen-specific humoral immune response in mice. Importantly, GMMA promote enhanced immunogenicity compared to traditional formulations (e.g., recombinant proteins and glycoconjugate vaccines), without negative impact to the anti-GMMA immune response. Our findings support the use of GMMA as a “plug and play” technology for the development of effective combination vaccines targeting different bugs at the same time.

31 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRossella Cioncada
Rossella Cioncada
MMMarcella Maddaluno
Marcella Maddaluno
Hoa VOHoa VO
Hoa VO
MWMatthew Woodruff
Matthew Woodruff
STSimona Tavarini
Simona Tavarini
DPDiego Piccioli
Diego Piccioli
MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an immunocompetent environment at injection site which promotes recruitment of immune cells, including antigen presenting cells (APCs), that are facilitated to engulf antigen and transport it to draining lymph node (dLN) where the antigen is accumulated. In vitro studies showed that MF59 promotes the differentiation of monocytes to dendritic cells (Mo-DCs). Since after immunization with MF59, monocytes are rapidly recruited both at the injection site and in dLN and appear to have a morphological change toward a DC-like phenotype, we asked whether MF59 could play a role in inducing differentiation of Mo-DC in vivo. To address this question we immunized mice with the auto-fluorescent protein Phycoerythrin (PE) as model antigen, in presence or absence of MF59. We measured the APC phenotype and their antigen uptake within dLNs, the antigen distribution within the dLN compartments and the humoral response to PE. In addition, using Ovalbumin as model antigen, we measured the capacity of dLN APCs to induce antigen-specific CD4 T cell proliferation. Here, we show, for the first time, that MF59 promotes differentiation of Mo-DCs within dLNs from intranodal recruited monocytes and we suggest that this differentiation could take place in the medullary compartment of the LN. In addition we show that the Mo-DC subset represents the major source of antigen-loaded and activated APCs within the dLN when immunizing with MF59. Interestingly, this finding correlates with the enhanced triggering of antigen-specific CD4 T cell response induced by LN APCs. This study therefore demonstrates that MF59 is able to promote an immunocompetent environment also directly within the dLN, offering a novel insight on the mechanism of action of vaccine adjuvants based on emulsions.

16 December 2021 in Expert Review of Vaccines
Verified
Journal Article
Open access
DPDiego Piccioli
Diego Piccioli
EBErika Bartolini
Erika Bartolini
FMFrancesca Micoli
Francesca Micoli
Generalized-Modules-for-Membrane-Antigens (GMMA) is a technology platform developed to design outer membrane vesicle (OMV)-based vaccines. GMMA are basically OMVs derived from a bacterial strain sp...

9 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Hoa VOHoa VO
Hoa VO
BBBarbara Christiane Baudner
Barbara Christiane Baudner
SSStefano Sammicheli
Stefano Sammicheli
MIMatteo Iannacone
Matteo Iannacone
UDUgo D'Oro
Ugo D'Oro
DPDiego Piccioli
Diego Piccioli
Vaccination is one of the most cost-effective health interventions and, with the exception of water sanitization, no other action has had such a major effect in mortality reduction. Combined with other approaches, such as clean water, better hygiene, and health education, vaccination contributed to prevent millions of cases of deaths among children under 5 years of age. New or improved vaccines are needed to fight some vaccine-preventable diseases that are still a threat for the public health globally, as reported also in the Global Vaccine Action Plan (GVAP) endorsed by the World Health Assembly in 2012. Adjuvants are substances that enhance the effectiveness of vaccination, but despite their critical role for the development of novel vaccines, very few of them are approved for use in humans. Aluminum hydroxide (Alum) is the most common adjuvant used in vaccines administered in millions of doses around the world to prevent several dangerous diseases. The development of an improved version of Alum can help to design and produce new or better vaccines. Alum/toll-like receptor (TLR)7 is a novel Alum-based adjuvant, currently in phase I clinical development, formed by the attachment of a benzonaphthyridine compound, TLR7 agonist, to Alum. In preclinical studies, Alum/TLR7 showed a superior adjuvant capacity, compared to Alum, in several disease models, such as meningococcal meningitis, anthrax, staphylococcus infections. None of these studies reported the effect of Alum/TLR7 on the generation of the B cell memory compartment, despite this is a critical aspect to achieve a better immunization. In this study, we show, for the first time, that, compared to Alum, Alum/TLR7 enhances the expansion of the memory B cell compartment within the draining lymph node (LN) as result of intranodal sustained proliferation of antigen-engaged B cells and/or accumulation of memory B cells. In addition, we observed that Alum/TLR7 induces a recruitment of naïve antigen-specific B cells within the draining LN that may help to sustain the germinal center reaction. Our data further support Alum/TLR7 as a new promising adjuvant, which might contribute to meet the expectations of the GVAP for 2020 and beyond.

Verified
Journal Article
Open access
PDF file
FMFrancesca Mancini
Francesca Mancini
RARenzo Alfini
Renzo Alfini
Valentina CaradonnaValentina Caradonna
Valentina Caradonna
VMValentina Monaci
Valentina Monaci
MCMartina Carducci
Martina Carducci
Francesca MicoliFrancesca Micoli
Francesca Micoli
Shigellosis is the leading cause of diarrheal disease, especially in children of low- and middle-income countries, and is often associated with anti-microbial resistance. Currently, there are no licensed vaccines widely available against Shigella, but several candidates based on the O-antigen (OAg) portion of lipopolysaccharides are in development. We have proposed Generalized Modules for Membrane Antigens (GMMA) as an innovative delivery system for OAg, and a quadrivalent vaccine candidate containing GMMA from S. sonnei and three prevalent S. flexneri serotypes (1b, 2a and 3a) is moving to a phase II clinical trial, with the aim to elicit broad protection against Shigella. GMMA are able to induce anti-OAg-specific functional IgG responses in animal models and healthy adults. We have previously demonstrated that antibodies against protein antigens are also generated upon immunization with S. sonnei GMMA. In this work, we show that a quadrivalent Shigella GMMA-based vaccine is able to promote a humoral response against OAg and proteins of all GMMA types contained in the investigational vaccine. Proteins contained in GMMA provide T cell help as GMMA elicit a stronger anti-OAg IgG response in wild type than in T cell-deficient mice. Additionally, we observed that only the trigger of Toll-like Receptor (TLR) 4 and not of TLR2 contributed to GMMA immunogenicity. In conclusion, when tested in mice, GMMA of a quadrivalent Shigella vaccine candidate combine both adjuvant and carrier activities which allow an increase in the low immunogenic properties of carbohydrate antigens.

5 September 2019 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
LMLaurye Van Maele
Laurye Van Maele
DFDelphine Fougeron
Delphine Fougeron
DCDelphine Cayet
Delphine Cayet
ACAurélie Chalon
Aurélie Chalon
DPDiego Piccioli
Diego Piccioli
ADArnaud M Didierlaurent
Arnaud M Didierlaurent
The 3‐O‐desacyl‐4’‐monophosphoryl lipid A (MPL) activates immunity through Toll‐like receptor 4 (TLR4) signaling. The Adjuvant System AS01 contains MPL and is used in the candidate malaria vaccine and the licensed zoster vaccine. Recent studies reported that AS01 adjuvant activity depends on a transient inflammation at the site of vaccination, but the role of stromal or structural cells in the adjuvant effect is unknown. We investigated this question in mouse models by assessing the role of TLR4 on hematopoietic versus resident structural cells during immunization with AS01‐adjuvanted vaccines. We first established that TLR4‐deficient animals had a reduced immune response to an AS01‐adjuvanted vaccine. Using bone marrow chimera, we consistently found that Tlr4 expression in radio‐sensitive cells, i.e., hematopoietic cells, was required for an optimal adjuvant effect on antibody and T‐cell responses. At day 1 after injection, the pro‐inflammatory reaction at the site of injection was strongly dependent on TLR4 signaling in hematopoietic cells. Similarly, activation of dendritic cells in muscle‐draining lymph nodes was strictly associated with the radio‐sensitive cells expressing Tlr4. Altogether, these data suggest that MPL‐mediated TLR4‐signaling in hematopoietic cells is critical in the mode of action of AS01.